Past, current and future possibilities for RCC treatments
Modified from Stukalin, Alimohamed & Heng. Oncol Rev 2016
Past
Sunitinib/
Pazopanib
Everolimus/
Axitinib
Whatever is
left
Present
Sunitinib/
Pazopanib
Nivolumab/
Cabozantinib/
Axitinib
Everolimus/
Therapy not
previously used
Future?
VHL/angiogenesis driven biomarker
Immune positive signature
TAM, MET or FGFR aberrations
TSC, PTEN, PI3K, mTOR mutations
TKIs
CPIs
Cabo/ Lenva
mTOR inh
